Cargando…
P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Autores principales: | Jurczak, Wojciech, Ghesquieres, Herve, Karimi, Yasmin, Cheah, Chan, Roost Clausen, Michael, Cunningham, David, Rok Do, Young, Lewis, David, Gasiorowski, Robin, Min Kim, Tae, Poel, Marjolein Van Der, Limei Poon, Michelle, Feldman, Tatyana, Linton, Kim, Sureda, Anna, Hutchings, Martin, Kanoun, Salim, Vercellino, Laetitia, Cota Stirner, Mariana, Mcgoldrick, Stephanie, Liu, Yan, Sacchi, Mariana, Lugtenburg, Pieternella, Thieblemont, Catherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431155/ http://dx.doi.org/10.1097/01.HS9.0000971368.08106.5c |
Ejemplares similares
-
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023) -
P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE
por: Roost Clausen, Michael, et al.
Publicado: (2023) -
S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
por: Sureda, Anna, et al.
Publicado: (2023) -
Drosophila melanogaster White Mutant w(1118) Undergo Retinal Degeneration
por: Ferreiro, María José, et al.
Publicado: (2018) -
Reaffirming a long-standing partnership
Publicado: (2010)